Equities analysts forecast that Proteostasis Therapeutics, Inc. (NASDAQ:PTI) will announce $1.38 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Proteostasis Therapeutics’ earnings, with the lowest sales estimate coming in at $1.03 million and the highest estimate coming in at $1.72 million. Proteostasis Therapeutics posted sales of $1.72 million during the same quarter last year, which would indicate a negative year over year growth rate of 19.8%. The business is expected to report its next earnings report on Thursday, November 9th.

On average, analysts expect that Proteostasis Therapeutics will report full year sales of $1.38 million for the current financial year, with estimates ranging from $2.17 million to $5.50 million. For the next year, analysts forecast that the business will post sales of $2.00 million per share. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Proteostasis Therapeutics.

Several analysts have recently commented on the stock. Leerink Swann reissued an “outperform” rating and set a $9.00 price target (down from $17.00) on shares of Proteostasis Therapeutics in a research note on Wednesday, August 16th. Zacks Investment Research raised shares of Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th.

Shares of Proteostasis Therapeutics (NASDAQ PTI) opened at 1.98 on Monday. The company’s 50-day moving average price is $2.07 and its 200 day moving average price is $3.50. The company’s market cap is $49.70 million. Proteostasis Therapeutics has a one year low of $1.71 and a one year high of $16.67.

COPYRIGHT VIOLATION NOTICE: “$1.38 Million in Sales Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/30/1-38-million-in-sales-expected-for-proteostasis-therapeutics-inc-pti-this-quarter-4.html.

A number of hedge funds have recently made changes to their positions in PTI. Russell Investments Group Ltd. bought a new position in Proteostasis Therapeutics in the first quarter valued at approximately $100,000. LMR Partners LLP bought a new position in Proteostasis Therapeutics in the second quarter valued at approximately $127,000. Goldman Sachs Group Inc. boosted its stake in Proteostasis Therapeutics by 364.3% in the second quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock valued at $243,000 after acquiring an additional 40,731 shares during the last quarter. Susquehanna International Group LLP bought a new position in Proteostasis Therapeutics in the second quarter valued at approximately $254,000. Finally, Bank of New York Mellon Corp boosted its stake in Proteostasis Therapeutics by 17.3% in the first quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock valued at $273,000 after acquiring an additional 5,153 shares during the last quarter. 73.70% of the stock is currently owned by hedge funds and other institutional investors.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.